Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GPR3 | P46089 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | PRKCI | P41743 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29211322 | 0.74 | KDM4E (0.45) | KDM4EGPR3ALDH1A1PARP1PRKCI | |
| SCHEMBL1068328 | 0.68 | ALDH1A1 (0.35) | KDM4EALDH1A1HSD17B10MAPK1 | |
| SCHEMBL19748969 | 0.66 | KDM4E (0.54) | KDM4EGPR3ALDH1A1PARP1PRKCI | |
| SCHEMBL2488607 | 0.66 | KDM4E (0.58) | KDM4EGPR3ALDH1A1PARP1PRKCI | |
| SCHEMBL3194830 | 0.66 | MAPK1 (0.37) | KDM4EGPR3ALDH1A1PARP1PRKCI | |
| SCHEMBL16740689 | 0.64 | KDM4E (0.47) | KDM4EGPR3ALDH1A1PARP1PRKCI | |
| SCHEMBL3192821 | 0.61 | ALDH1A1 (0.40) | KDM4EGPR3ALDH1A1PARP1PRKCI | |
| SCHEMBL19820713 | 0.59 | KDM4E (0.56) | KDM4EGPR3ALDH1A1PARP1PRKCI | |
| SCHEMBL10742095 | 0.59 | KDM4E (0.48) | KDM4EGPR3ALDH1A1HSD17B10 | |
| SCHEMBL18099793 | 0.58 | KDM4E (0.53) | KDM4EGPR3ALDH1A1PARP1PRKCI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067655-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. | 2024-02-29 | — | — | US | disclosed |
| EP-4243816-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | Neuron23, Inc. (US) | 2023-09-20 | — | — | EP | disclosed |
| WO-2022104206-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | NEURON23, INC. (US) | 2022-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067655-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | TYK2, NUAK1, NUAK2 | KDM4E 2161/4885GPR3 1139/4885ALDH1A1 4504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.